Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dogwood Therapeutics, Inc.DWTX · Entity 6845 | Chief Financial Officer | March 05, 2026 | March 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dogwood Therapeutics, Inc.
Report date March 05, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.86 · Expires 2036-03-05 | Direct | 82,500 |
Reported balance
After 2026-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 82,500 · Balance 82,500 F1: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 6, 2026 21:18 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001825987-26-000002 · form4-03062026_090340.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2036-03-05 F1 · derivative.exercise_date: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:05 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001825987-25-000005 · form4-12052025_041205.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-12-04 F1 · derivative.exercise_date: The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 17:56 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 12,075 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001415889-25-018638 · form4-07012025_050708.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,075 Underlying: Common Stock · 12,075 shares Expires 2035-06-27 F1 · derivative.exercise_date: The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 17:51 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 63,618 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-24-005672 · form4-02282024_050228.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,618 Underlying: Common Stock · 63,618 shares Expires 2034-02-26 F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 23:32 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001415889-22-012560 · form4-12142022_111252.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-12-12 F1 · derivative.exercise_date: The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 17:40 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007078 · form4-06302022_100642.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter. Read SEC document |
| May 23, 2022 Filed May 24, 2022 18:53 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 2,000 | $4.58 | $9,150.00 |
DisclosureSEC source: 0001415889-22-005575 · form4-05242022_110533.xml · nonDerivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 3,000 Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 21:05 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001415889-21-003146 · form4-06222021_020636.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: The stock option vests one-third on June 21, 2022 and 1/24th monthly thereafter. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 00:54 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 1,000 | $7.30 | $7,300.00 |
DisclosureSEC source: 0001104659-21-010387 · tm214953-3_4seq1.xml · nonDerivative · entry 1 Walsh Angela · CIK 0001825987 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 1,000 Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 00:44 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 209 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-21-003573 · tm212264d3_4.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,621 Underlying: Common Stock · 209 shares Expires 2030-12-21 F1 · kind: Stock options granted pursuant to the reporting person's employment agreement. Pursuant to that employment agreement, the reporting person was entitled to receive a total of 41,621 stock options. In error, the Issuer previously granted only 41,412. This grant was made solely to correct the error in the number of stock options granted under the reporting person's employment agreement. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 01:11 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 41,412 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138200 · tm2039099-2_4.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,412 Underlying: Common Stock · 41,412 shares Expires 2030-12-21 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.